A Phase I/II Study of Second-Line Chemotherapy with Fractionated Docetaxel and Nedaplatin for 5-FU/Cisplatin-Resistant Esophageal Squamous Cell Carcinoma

作者：Akutsu Yasunori^*; Shuto Kiyohiko; Kono Tsuguaki; Uesato Masaya; Hoshino Isamu; Shiratori Toru; Miyazawa Yukimasa; Isozaki Yuka; Akanuma Naoki; Matsubara Hisahiro

来源：Hepato-Gastroenterology, 2012, 59(119): 2095-2098.

DOI：10.5754/hge11952

• Esophageal cancer
• Chemotherapy
• Docetaxel
• Nedaplatin

Background/Aims: There are few second-line regimens available for esophageal cancer. The use of fractionated docetaxel and nedaplatin as second-line chemotherapy was examined in this study. Methodology: Eligibility criteria were follows: histologically-proven squamous cell carcinoma, surgically unresectable disease, failure to respond to chemotherapy with 5-FU and cisplatin and no more than 2 prior chemotherapy regimens. A total of 12 patients were enrolled in this study. To reduce toxicities, fractionated docetaxel (50mg/m(2) in day 1 and 8) and nedaplatin (50mg/m2 in day 8) were administered as second-line chemotherapy. Results: Stable disease (SD) was observed in 4 cases (33%) and the disease control rate was 33%. Regarding toxicities, leukopenia was the most frequently observed (8 cases, 67%); however, there were no cases of grade 4 non-hematological toxicity. The 1-year overall survival was 26.7% and the median survival time was 7.8 months (95% CI=3.328-12.272 months). The 1-year progression-free survival was 0% and the median progression-free time was 2.0 months (95% CI=1.319-2.681). Conclusions: Combination chemotherapy using fractionated docetaxel and nedaplatin is safe and effective and appears to be a feasible regimen to use as second-line chemotherapy for FP-resistant advanced esophageal squamous cell carcinoma.

• 出版日期2012-10